Introduction:Basic information about CAS 111011-53-1|Efonidipine (hydrochloride), including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Efonidipine (hydrochloride) |
|---|
| CAS Number | 111011-53-1 | Molecular Weight | 668.11600 |
|---|
| Density | / | Boiling Point | 746.9ºC at 760 mmHg |
|---|
| Molecular Formula | C34H39ClN3O7P | Melting Point | 169-170ºC |
|---|
| MSDS | USA | Flash Point | 405.5ºC |
|---|
Names
| Name | 2-(N-benzylanilino)ethyl 5-(5,5-dimethyl-2-oxo-1,3,2λ5-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate,hydrochloride |
|---|
| Synonym | More Synonyms |
|---|
Efonidipine (hydrochloride) BiologicalActivity
| Description | Efonidipine Hcl (NZ-105) is a dual T-type and L-type calcium channel blocker (CCB).IC50 value: Target: calcium channel blockerin vitro: Efonidipine and nifedipine, but not other examined CCBs, also increased the N(6), 2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (dbcAMP)-induced StAR mRNA, which reflects the action of adrenocorticotropic hormone, and efonidipine and R(-)-efonidipine enhanced the dbcAMP-induced DHEA-S production in NCI-H295R adrenocortical carcinoma cells [1]. I(Ca(T)) was blocked mainly by a tonic manner by nifedipine, by a use-dependent manner by mibefradil, and by a combination of both manners by efonidipine. IC50s of these Ca2+ channel antagonists to I(Ca(T)) and L-type Ca2+ channel current (I(Ca(L))) were 1.2 micromol/l and 0.14 nmol/l for nifedipine; 0.87 and 1.4 micromol/l for mibefradil, and 0.35 micromol/l and 1.8 nmol/l for efonidipine, respectively [4].in vivo: Twenty hypertensive patients on chronic hemodialysis were given efonidipine 20-60 mg twice daily and amlodipine 2.5-7.5 mg once daily for 12 weeks each in a random crossover manner. The average blood pressure was comparable between the efonidipine and amlodipine periods (151 + or - 15/77 + or - 8 versus 153 + or - 15/76 + or - 8 mmHg). The pulse rate did not change significantly during the administration periods [2]. In the UM-X7.1 group, EFO treatment significantly attenuated the decrease of LVEF without affecting blood pressure compared with the vehicle group. EFO treatment decreased heart rate (by approximately 10%) in both groups [3]. |
|---|
| Related Catalog | Signaling Pathways >>Membrane Transporter/Ion Channel >>Calcium ChannelResearch Areas >>Cardiovascular Disease |
|---|
| References | [1]. Ikeda K, et al. Efonidipine, a Ca(2+)-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells. Tohoku J Exp Med. 2011;224(4):263-71. [2]. Nakano N, et al. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. Int Heart J. 2010 May;51(3):188-92. [3]. Suzuki S, et al. Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters. Circ J. 2007 Dec;71(12):1970-6. [4]. Lee TS, et al. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. Pharmacology. 2006;78(1):11-20. |
|---|
Chemical & Physical Properties
| Boiling Point | 746.9ºC at 760 mmHg |
|---|
| Melting Point | 169-170ºC |
|---|
| Molecular Formula | C34H39ClN3O7P |
|---|
| Molecular Weight | 668.11600 |
|---|
| Flash Point | 405.5ºC |
|---|
| Exact Mass | 667.22100 |
|---|
| PSA | 132.73000 |
|---|
| LogP | 8.95720 |
|---|
| Vapour Pressure | 3.5E-22mmHg at 25°C |
|---|
| InChIKey | OXVTXPCIJDYQIS-UHFFFAOYSA-N |
|---|
| SMILES | CC1=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)C(c2cccc([N+](=O)[O-])c2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1.Cl |
|---|
| Storage condition | 2-8℃ |
|---|
Synonyms
| Efonidipine HCl |
| NZ 105 |
| C34H38N3O7P.Cl |
| efonidipine hydrochloride |
| Efonidipine (hydrochloride) |